Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Cancer Center Amsterdam, Amsterdam, The Netherlands.
Disaster Med Public Health Prep. 2024 Oct 30;18:e243. doi: 10.1017/dmp.2024.176.
The impact of the coronavirus disease 2019 (COVID-19) on hepatocellular carcinoma (HCC) care is unclear. This study reports on HCC patterns during the COVID-19 pandemic in the Netherlands.
Patients diagnosed with HCC between 2017 and 2020 were identified from the Netherlands Cancer Registration. Monthly incidence rates were compared between 2020 and 2017-2019. Patient, tumor, process, and treatment characteristics and survival were compared between 2020 and 2017-2019, and between COVID-high (April and May 2020) and COVID-low (June and July 2020) months.
The incidence of HCC was lower in May 2020 (IRR 0.56, = 0.001) and higher in June 2020 (IRR 1.32, = 0.05) compared to the same months in 2017-2019. In 2017-2019, 2134 patients presented with HCC, compared to 660 in 2020. Time-to-treatment was shorter in 2020 (median 60 vs. 70 days, < 0.001). The percentage of patients undergoing any treatment did not differ, yet if treatment was not performed this was more commonly due to comorbidity in 2020 (52 vs. 39%, < 0.001). No other differences were found in patient, tumor, process and treatment characteristics and survival between COVID-high and COVID-low months.
This study demonstrated no impact of the COVID-19 pandemic on HCC patients, despite a decrease in HCC diagnoses.
2019 年冠状病毒病（COVID-19）对肝细胞癌（HCC）治疗的影响尚不清楚。本研究报告了 COVID-19 大流行期间荷兰 HCC 的发病模式。
从荷兰癌症登记处确定了 2017 年至 2020 年期间诊断为 HCC 的患者。比较了 2020 年与 2017-2019 年之间的每月发病率。比较了 2020 年与 2017-2019 年之间以及 COVID-高发（2020 年 4 月和 5 月）和 COVID-低发（2020 年 6 月和 7 月）期间的患者、肿瘤、治疗过程和治疗特征以及生存率。
与 2017-2019 年同期相比，2020 年 5 月 HCC 发病率较低（IRR0.56，=0.001），2020 年 6 月发病率较高（IRR1.32，=0.05）。2017-2019 年期间有 2134 例患者出现 HCC，而 2020 年有 660 例。2020 年的治疗时间更短（中位数 60 天对 70 天，<0.001）。接受任何治疗的患者比例没有差异，但如果未进行治疗，则 2020 年更多地是由于合并症（52%比 39%，<0.001）。在患者、肿瘤、治疗过程和治疗特征以及生存率方面，COVID-高发和 COVID-低发月份之间没有发现其他差异。
尽管 HCC 诊断减少，但本研究表明 COVID-19 大流行对 HCC 患者没有影响。
